Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event
June 22, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual Meeting
June 06, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
Survey conducted in collaboration with the Depression and Bipolar Support Alliance (DBSA) Survey respondents reported persistence of high levels of depressive symptoms and interference with work and...
Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder
June 02, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
AXS-05 rapidly and significantly improved anhedonic symptoms, measured by the MADRS anhedonia subscale, starting 1 week after treatment Data being presented at the American Society of Clinical...
Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting
June 01, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
Rapid, substantial, and durable improvement in depressive symptoms (MADRS), and functioning (SDS) with AXS-05, sustained over 12 months, (p<0.001 for all vs. baseline) Rapid, substantial, and...
Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry
May 31, 2022 07:39 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
May 09, 2022 08:57 ET
|
Axsome Therapeutics, Inc.
Axsome is committed to providing patients uninterrupted access to Sunosi and advancing research for patients living with sleep disorders Insurance coverage for Sunosi totals 96% of commercial lives...
Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience
March 28, 2022 06:00 ET
|
Axsome Therapeutics, Inc.
Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated...
Axsome Therapeutics to Participate in the 1st Annual Needham Virtual Neuroscience Forum
March 11, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, March 11, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
March 02, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 01, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel...